logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Lenalidomide in addition to R-CHOP chemotherapy for diffuse large B-cell lymphoma

< Back

Lenalidomide in addition to R-CHOP chemotherapy for diffuse large B-cell lymphoma

Drugs

Cancer and Palliative Care

March 2019


Lenalidomide in addition to a chemotherapy combination known as R-CHOP is in clinical development for newly diagnosed, previously untreated adult patients with diffuse large B-cell lymphoma (DLBCL) of the subtype known as activated B-cells (ABC) type. DLBCL is a cancer affecting a type of white blood cells called lymphocytes or B-cells. It is the most common form of non-Hodgkin lymphoma among adults. DLBCL is an aggressive cancer and although it can be cured in more than half of people affected, it remains a serious and life threatening disease. Treatment does not work as well for patients with the ABC type compared to patients with other DLBCL types who receive standard treatment.
Lenalidomide is a derivative of thalidomide and in DLBCL works by blocking the development of tumour cells, preventing the growth of blood vessels within tumours and stimulating some of the specialised cells of the immune system to attack the cancerous cells. It is administered orally in addition to current standard of therapy R-CHOP. The addition of lenalidomide to R-CHOP for this population subgroup may improve effectiveness and prognosis.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts